Chongqing Pharscin Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A carries a market capitalization of 5.54B, placing it among publicly traded companies globally. Its enterprise value stands at 5.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A has 417.60M shares outstanding.

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 80.07. The price-to-sales ratio is 6.78, and the price-to-book ratio stands at 3.19.

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 61.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 61.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.01B versus a market cap of 5.54B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A maintains a current ratio of 4.65, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.39, indicating elevated leverage, while an interest coverage ratio of 97.21 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 4.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.75 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.72, useful for judging operating efficiency across full business cycles. The company generates approximately 573,760.47 in revenue per employee across its workforce of 1,425.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.77 indicates how many times Chongqing Pharscin Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A recorded 13.35M in income tax expense. That works out to an effective tax rate of 19.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 68.53M, leaving 69.21M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A's stock has declined approximately 19.01% over the past 52 weeks. The 50-day moving average sits at 14.59, while the 200-day moving average is 14.05.

Over the twelve months ended June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A generated 817.75M in revenue and converted that into 69.21M in net income, yielding earnings per share of 0.13. EBITDA reached 81.97M, while operating income came in at 69.25M.

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A holds 579.95M in cash and equivalents against 41.76M in total debt, resulting in a net debt position of -299.16M. Total book value stands at 1.74B, with working capital of 921.42M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A posted a gross margin of 57.89, reflecting its pricing power and cost economics. The operating margin of 8.47 and net profit margin of 8.46 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A paid dividends of -NaN per share. The dividend payout ratio of 0.00 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.76, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chongqing Pharscin Pharmaceutical Co., Ltd. Class A shareholders.

As of June 30, 2026, Chongqing Pharscin Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 12.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.